{"product_id":"ildong-business-model-canvas","title":"Ildong Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong Pharmaceuticals: Compact Business Model Canvas \u0026amp; Templates for Strategic Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Ildong Pharmaceuticals's business model—this concise Business Model Canvas maps value propositions, key partners, revenue streams, and growth levers to reveal how the company competes and scales in pharma markets; ideal for investors, consultants, and entrepreneurs seeking actionable insights and ready-to-use Word\/Excel templates to accelerate strategic analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong partners with global pharma firms to co-develop and license drugs for Korea, notably a multi-decade collaboration with Shionogi on antivirals that helped drive Ildong’s 2024 oncology\/infectious revenue to KRW 85.2 billion (up 12% YoY).\u003c\/p\u003e\n\u003cp\u003eThese alliances give Ildong access to advanced platforms and licensing fees; in 2023–24 licensing deals added ~KRW 18.5 billion, boosting its pipeline in infectious diseases and metabolic health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals partners with top universities and biotech centers to pipeline early-stage drug discovery, especially in oncology and immunology, converting academic leads into clinical candidates; in 2024 these collaborations accounted for roughly 18% of R\u0026amp;D project starts and supported three IND filings. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals depends on a network of chemical and biologic suppliers—over 120 approved vendors as of 2025—to secure active pharmaceutical ingredients (APIs) that uphold drug efficacy; stable contracts cut supply disruption risk and helped lower COGS by ~4% in FY2024. Suppliers must meet GMP and ISO 9001 standards and EU\/US regulatory specs to keep approval timelines and control quality-related recall costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals contracts specialized third-party logistics (3PL) providers to handle cold-chain storage and transport, ensuring temperature-sensitive drugs arrive at hospitals, clinics, and pharmacies across South Korea in optimal condition; in 2024 Ildong reported \u0026gt;95% on-time delivery for cold-chain products and cut spoilage below 1.2%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3PLs manage -20°C to 8°C ranges\u003c\/li\u003e\n\u003cli\u003e95%+ on-time delivery (2024)\u003c\/li\u003e\n\u003cli\u003eSpoilage \u0026lt;1.2% (2024)\u003c\/li\u003e\n\u003cli\u003eNationwide reach: 1,500+ healthcare sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with major medical centers enable Ildong Pharmaceuticals to run late-stage clinical trials and collect real-world evidence, tapping hospital patient pools (Korea’s tertiary hospitals treated ~12 million inpatients in 2024) and infrastructure for regulatory filings.\u003c\/p\u003e\n\u003cp\u003eThese partnerships speed recruitment, lower trial costs, and support physician education—Ildong ran 8 hospital-led investigator studies in 2024—strengthening adoption of new therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to large patient cohorts (multi-center reach)\u003c\/li\u003e\n\u003cli\u003eReduced trial timelines and costs\u003c\/li\u003e\n\u003cli\u003eReal-world data for approvals and reimbursement\u003c\/li\u003e\n\u003cli\u003ePhysician training and prescribing uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong partnerships drive KRW85.2b revenue, 95%+ cold-chain reliability, 3 INDs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong’s key partners—global pharma (eg Shionogi), 120+ API suppliers, 3PLs, top hospitals and universities—delivered KRW 85.2b oncology\/infectious revenue (2024), KRW 18.5b licensing income (2023–24), 95%+ cold-chain on-time delivery and \u0026lt;1.2% spoilage (2024); partnerships drove ~18% of R\u0026amp;D starts and three INDs in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal pharma\u003c\/td\u003e\n\u003ctd\u003eOncology\/infectious rev\u003c\/td\u003e\n\u003ctd\u003eKRW 85.2b (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing deals\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eKRW 18.5b (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eApproved vendors\u003c\/td\u003e\n\u003ctd\u003e120+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3PLs\u003c\/td\u003e\n\u003ctd\u003eOn-time \/ spoilage\u003c\/td\u003e\n\u003ctd\u003e95%+ \/ \u0026lt;1.2% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcad \u0026amp; hospitals\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D starts \/ INDs\u003c\/td\u003e\n\u003ctd\u003e~18% \/ 3 INDs (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Ildong Pharmaceuticals outlining customer segments (hospitals, clinics, pharmacies, patients, global partners), value propositions (proprietary drug formulations, generics, strong R\u0026amp;D, patient support), channels (direct sales, distributors, online platforms), key activities\/resources\/partners (R\u0026amp;D, manufacturing, CROs, licensing), revenue streams\/cost structure, plus SWOT-linked insights for investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ildong Pharmaceuticals’ strategy into a digestible one-page Business Model Canvas that relieves the pain of fragmented planning and saves hours of structuring for boardrooms, teams, or quick executive reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals invests ~KRW 120 billion (2024 R\u0026amp;D spend) to discover new chemical entities and biologics for unmet needs, concentrating lab research and phase I–III clinical trial management in metabolic diseases and oncology; pipeline includes 6 clinical-stage assets and aims for 2–3 new product launches per year to sustain revenue growth and market competitiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP Certified Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals runs GMP (Good Manufacturing Practice) certified plants producing tablets, injections, and specialty supplements, supporting annual finished-goods output exceeding 200 million units (2024). Continuous process optimization cut batch cycle time by 12% and lowered solvent waste 18% year-on-year, helping maintain product safety, reduce COGS per unit, and comply with global export standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong runs extensive promotional campaigns to boost OTC and prescription brands, reporting marketing spend of ~KRW 120 billion in 2024 and aiming to raise market share in respiratory and gastrointestinal segments by 2–3 percentage points. The sales force of ~1,800 reps meets healthcare professionals to convey clinical benefits, while data-driven targeting—using patient claims and CRM analytics—directs campaigns to high-value demographics to maximize uptake and ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance with South Korea’s Ministry of Food and Drug Safety is central: Ildong spent ₩42.3 billion on regulatory and quality functions in 2024 to secure approvals and post-market surveillance for 120+ active products.\u003c\/p\u003e\n\u003cp\u003eQuality assurance teams run quarterly audits, batch testing with ≤1% out-of-spec rates, and continuous pharmacovigilance to protect safety, efficacy, and the Ildong brand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e₩42.3B regulatory spend (2024)\u003c\/li\u003e\n\u003cli\u003e120+ approved products\u003c\/li\u003e\n\u003cli\u003eQuarterly audits; ≤1% out-of-spec rate\u003c\/li\u003e\n\u003cli\u003eOngoing pharmacovigilance and post-market surveillance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong manages flow from raw materials to delivery using inventory forecasting, warehouse control, and logistics partnerships to cut lead times and lower costs.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Ildong reported supply-chain-driven cost savings of KRW 12.8 billion and reduced order-to-delivery time by 18%, improving responsiveness to market demand shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInventory turns up 14% (2024)\u003c\/li\u003e\n\u003cli\u003eWarehousing across 6 hubs in Korea\u003c\/li\u003e\n\u003cli\u003e3PL partners for export to 20 countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong: KRW120B R\u0026amp;D, 6 clinical assets, \u0026gt;200M units, strong ops \u0026amp; KRW12.8B supply savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong runs R\u0026amp;D (KRW 120B, 2024), 6 clinical assets, targets 2–3 launches\/yr; GMP plants produce \u0026gt;200M units\/yr, cut batch time 12%, solvent waste 18%; marketing KRW 120B, 1,800 reps; regulatory KRW 42.3B, 120+ products; supply-chain savings KRW 12.8B, order-to-delivery −18%, inventory turns +14% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eKRW 120B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical assets\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinished units\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003eKRW 120B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003eKRW 42.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply savings\u003c\/td\u003e\n\u003ctd\u003eKRW 12.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing here is the actual Ildong Pharmaceuticals Business Model Canvas—not a mockup or sample—and it reflects the exact structure and content you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order, you'll get this same professional, ready-to-edit file in full (Word and Excel), with all sections, pages, and details included—no surprises, no fillers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748987875705,"sku":"ildong-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ildong-business-model-canvas.png?v=1772212182","url":"https:\/\/matrixbcg.com\/products\/ildong-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}